Keywords: Quantitative Imaging, Cancer, Diagnosis/Prediction
Motivation: Accurate differentiation of human epidermal growth factor receptor 2 (HER2) expression status in breast cancer (BC) is essential for selecting appropriate targeted therapies. Current diagnostic methods have limitations in identifying low HER2 expression levels, necessitating more efficient, non-invasive techniques.
Goal(s): To evaluate the feasibility of using ultrafast dynamic contrast-enhanced MRI (UF-DCE MRI) to distinguish HER2 expression statuses in BC.
Approach: 398 histopathologically-confirmed BC patients underwent UF-DCE MRI. Five UF-DCE MRI-derived parameters were analyzed to assess their diagnostic performance.
Results: UF-DCE MRI parameters showed significant differences between HER2-Zero, HER2-Low, and HER2-Positive subtypes, though diagnostic performance was moderate.
Impact: This research demonstrates that UF-DCE MRI could provide a non-invasive method for distinguishing HER2 expression levels in BC, aiding in selecting appropriate therapies. It has the potential to improve personalized treatment approaches and influence future clinical practice in HER2-targeted therapies.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords